PalmGen Group Makes a Big Leap to Management Innovation and Shared Growth in 2025
Jan 06, 2025
On the 6th, PalmGen Group (Chairman Han Eui-sang) announced that it held the '2025 PalmGen Group Demonstration' at L Tower in Seocho-gu, Seoul on the 3rd.
Starting with the memorial service for the victims of Muan Airport, the ceremony was held in the order of awarding model awards to eight executives and employees who contributed significantly to sales growth and cost reduction in 2024, announcing business plans for each affiliate, and New Year's address for the chairman.
▲ Global pharmaceutical and bio companies, including ▲ PharmGenScience, ▲ Global In vitro diagnostic and digital healthcare company Access Bio ▲ Concern Comprehensive Diagnostic Solutions, Wells Bio ▲ PalmGen Group investment company, and ▲ Pharmaceutical technology-based healthcare distributor Incubent gathered in one place and were shared with domestic and foreign executives through live online broadcasts.
FarmGenScience has set its main management goals this year to establish a virtuous profit cycle structure and secure new growth engines, AccessBio strengthens its LDT business and digital healthcare new business, WellsBio establishes an ultra-personalized health care solution through multi-modal AI analysis services, Beright Investment establishes an integrated investment strategy for group companies by discovering differentiated business opportunities for business synergy, and Incubenten sets its main management goals for this year's brand enhancement through enhancing its primary competitiveness.
In his New Year's address, Chairman Han Eui-sang of Palm Zen Group said, "2042 is a significant year for Palm Zen Group, which has achieved non-clinical tasks for national new drug development projects through challenges and innovation amid continued political and economic uncertainties around the world after COVID-19. We look forward to the company's greater leap forward in 2025 with the goal of people-centered management innovation and sustainable shared growth," he said.
Starting with the memorial service for the victims of Muan Airport, the ceremony was held in the order of awarding model awards to eight executives and employees who contributed significantly to sales growth and cost reduction in 2024, announcing business plans for each affiliate, and New Year's address for the chairman.
▲ Global pharmaceutical and bio companies, including ▲ PharmGenScience, ▲ Global In vitro diagnostic and digital healthcare company Access Bio ▲ Concern Comprehensive Diagnostic Solutions, Wells Bio ▲ PalmGen Group investment company, and ▲ Pharmaceutical technology-based healthcare distributor Incubent gathered in one place and were shared with domestic and foreign executives through live online broadcasts.
FarmGenScience has set its main management goals this year to establish a virtuous profit cycle structure and secure new growth engines, AccessBio strengthens its LDT business and digital healthcare new business, WellsBio establishes an ultra-personalized health care solution through multi-modal AI analysis services, Beright Investment establishes an integrated investment strategy for group companies by discovering differentiated business opportunities for business synergy, and Incubenten sets its main management goals for this year's brand enhancement through enhancing its primary competitiveness.
In his New Year's address, Chairman Han Eui-sang of Palm Zen Group said, "2042 is a significant year for Palm Zen Group, which has achieved non-clinical tasks for national new drug development projects through challenges and innovation amid continued political and economic uncertainties around the world after COVID-19. We look forward to the company's greater leap forward in 2025 with the goal of people-centered management innovation and sustainable shared growth," he said.
|
This article was translated by Naver AI translator.
